Renal patients are overexposed to hepatitis C virus (HCV) infection. Hepatitis C virus infection may induce renal disease, i.e., cryoglobulinemic membrano-proliferative glomerulopathy and non-cryoglobulinemic nephropathy. Hepatitis C virus impacts general outcomes in chronic kidney disease, dialysis or transplanted patients.
INTRODUCTION
Hepatitis C virus (HCV) was discovered 25 years ago [1] and is now about to get a cure. In the meantime, the C virus has induced tremendous Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ D9D4F0607DE2BBA8. morbidity and mortality mainly due to liver complications (cirrhosis, hepatocellular carcinoma). However, many extrahepatic manifestations [2] have been reported for chronic HCV infection with increased related morbidity and mortality, including cardiovascular diseases, type 2 diabetes and insulin resistance, neurocognitive dysfunction, systemic vasculitis, B cell non-Hodgkin lymphoma and chronic kidney disease [3] . 
EPIDEMIOLOGY OF HEPATITIS C VIRUS INFECTION IN RENAL PATIENTS
Approximately 170 million people are infected with HCV worldwide and 2.35% of the total world population [4] . In dialysis patients, the prevalence of HCV infection has evolved dramatically over the last 10 years. In 2004, the Dialysis Outcomes and Practice Patterns Study (DOPPS) published the largest study analyzing the HCV serological status in 8615 randomly selected hemodialysis patients treated in 308 dialysis facilities (in 8 countries in Europe, HCV USA and Japan) [5] . It showed the HCV antibody prevalence to be 14.7% when unadjusted and 10.4% when adjusted for age, gender, race, time with end-stage renal disease, and alcohol or drug abuse in the past 12 months. The updated DOPPS study [6] found a very low prevalence of HCV treatment in dialysis patients as only 1% of the 4589 patients with available prescription data were receiving HCV medications. Among a subset of 617 HCV patients known to be on the waiting list for renal transplantation, only 3.7% were receiving HCV treatment. In the DOPPS study, the seropositivity for HCV was associated with black race [odds ratio (OR) = 1.93, P\0.0001], male gender (OR = 1.18, P = 0.01), diabetes mellitus (OR = 1.18, P = 0.03), a history of gastrointestinal bleeding (OR = 1.22, P = 0.06), HBV infection (OR = 2.56, P\0.0001) and prior renal transplant (OR = 1.34, P = 0.01). Drug and alcohol abuse, as reported during the 12 months prior to data collection, was also associated with HCV seropositivity (OR = 2.44, P\0.0001 and 1.75, P = 0.0001, respectively). At that time, the risk of seroconversion was variable despite infection control measures, and HCV outcomes varied by patient characteristics, country and hemodialysis facility practice patterns. No consensus was available with regard to the need for hemodialysis patient isolation and dedicated dialysis machines to prevent HCV transmission, in addition to blood-borne precautions [5] . Adjusted HCV seroconversions/100 patient-years ranged from 1.2 (0.7-2.0) in the UK to 3.9 (2.9-5.2) in Italy.
In 55.6% of facilities, the mean seroconversion rate was 0 per 100 patient-years. Seroconversion was mostly associated with the prevalence of HCV in the facility and with black race [relative risk (RR) = 1.42, P = 0.05], duration of end-stage renal disease (ESRD) therapy by year [with a 4% higher risk of seroconversion (P = 0.007)] and HIV/AIDS or HBV co-infection (RR = 3.29, P = 0.006 and RR = 2.16, P = 0.001, respectively). The authors concluded that this study provided evidence for nosocomial transmission of HCV in dialysis facilities but did not demonstrate that isolation of patients infected with HCV was associated with a decreased risk of HCV seroconversion. The major drawback in this work was the absence of HCV RNA analysis.
A more recent analysis, the DOPPS 5 study (2012-2015) [6] , included around 500 facilities and 17,000 patients in 21 countries. It showed that HCV prevalence among hemodialysis patients has declined in recent years in many DOPPS countries but remains higher than in the general population with a prevalence of 9.5% (in 11,394 patients). We generated the most recent analysis of the prevalence and incidence of HCV and HBV infections in end-stage renal disease patients in France from the REIN registry, a national prospective cohort including 72,948 patients who started dialysis or were preemptively transplanted. We found significantly lower prevalence of both HBV Transplanted patients are also exposed to HCV infection, mostly through their treatment with dialysis. However, a decrease in the frequency of HCV infection during dialysis has been mirrored by a decreased rate of HCV infection acquisition following renal transplantation [8] .
CLINICAL INVOLVEMENT OF KIDNEY DURING HEPATITIS C VIRUS INFECTION

Mixed Cryoglobulinemia Vasculitis
Mixed cryoglobulinemia vasculitis (CryoVas) [9] -a small vessel vasculitis involving mainly the skin, joints, peripheral nerve system and kidneys-is mainly due to HCV infection Cryoglobulinemia is confirmed by the detection of protein precipitates in the patient's serum maintained at 4°C for at least 7 days, which dissolved when heated at 37°C.
Biological improvement can be assessed by the quantification of cryoglobulinemia and C4 and CH50 levels [9] . During HCV infection, predictive factors for CryoVas are advanced age, longer duration of infection, type II mixed cryoglobulinemia, higher cryoglobulin serum levels and clonal B cell expansions in both the blood and liver [11] . The overall 5-year survival after the diagnosis of HCV-CryoVas ranges from 90% to 50%, the latter being reported in case of renal involvement [11] [12] [13] [14] . In a retrospective Italian study of 231 HCV-CryoVas patients [12] , 79 of 97 deaths were linked to vasculitis (46%, of which one-third were due to renal involvement). Life-threatening CryoVas complications are observed in up to 10% of the patients with almost two-thirds resulting in death [13] .
HCV-CryoVas may result in progressive (renal involvement) or acute (pulmonary hemorrhage, gastrointestinal ischemia, cardiac, CNS involvement) life-threatening organ damage. The mortality rate of these manifestations ranges between 20% and 80% [14, 15] . Age older than 60 years at diagnosis, the presence of a renal failure, intestinal ischemia, pulmonary hemorrhage, high cryocrit levels and type II mixed cryoglobulinemia are associated with severe prognosis [13] .
In HCV-infected patients, many factors have been described to predispose patients to a
CryoVas. Interaction between the virus and immune cells directly modulates B-and T-cell function resulting in expansion of B-cell production of IgM with RF activity [16] . The
CD4
? CD25 ? FoxP3 ? regulatory T cell number is significantly reduced [17, 18] , possibly leading to the expansion of peripheral auto-reactive B-cells.
HLA-DR11 is associated with HCV-CryoVas, whereas HLA-DR7 appears to protect patients from the production of type II mixed cryoglobulinemia [19] . In a large multicenter study significant associations were identified on chromosome 6, a SNP located within an intronic region of NOTCH4 (p = 6.2 9 10 -9 ), and another was found in between HLA-DRB1 and HLA-DQA1 (p = 1.2 9 10 -7 ) [20] . A higher percentage of a particular allele of the promoter of the B-cell activating factor and different expression patterns on circulating lymphocytes of microRNAs known to be involved in lymphoproliferative and/or autoimmune disorders have been shown [21, 22] . Specific virological factors have never been identified.
Non-Cryoglobulinemic Renal
Involvement in HCV-Infected Patients
Other glomerular diseases in both native [23] and transplanted kidneys [24] . Survival after transplantation was reported to be impacted negatively by a predisposition to progressive liver disease [8] . Besides, onset of new diabetes is significantly increased after transplantation potentially leading to metabolic complications.
TREATMENT OF HEPATITIS C INFECTION
In Patients with HCV-CryoVas Despite better efficacy and good tolerance in CKD patients, DAAs may not be available, and depending on the local conditions, older therapies such as PEG-interferons could still be offered with much less chance of SVR but at a lesser cost.
Other oral DDA combinations may be used in renal patients based on their hepatic metabolism. The risk of renal pharmacokinetic modifications in cirrhotic patients is high, and DAAs with hepatic metabolism in this context may not guarantee renal safety.
The HCV lifecycle can be blocked at many steps. HCV DAAs on the market or in clinical Table 2 Recent published guidelines for use of DAAs in CKD patients with comments from the latest publications
AASLD 2015
For patients with mild to moderate renal impairment (GFR [30-80 ml/min), no dosage adjustment is required when using sofosbuvir, simeprevir, a fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) or fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) to treat or retreat HCV infection in patients with appropriate genotypes (I-A)
For treatment-naive patients with HCV genotype 1 without cirrhosis with GFR \30 ml/min, treatment with the daily fixed-dose combination of paritaprevir (150 mg barrier to resistance. They also differ in terms of the hepatic and renal metabolism. Some good reviews offer tables that detail drug dosage adaptations in renal failure [73] . In Table 1 , we
give a recent update of DAA use in renal patients. However, many other studies are ongoing that will allow a better knowledge of their safety in real-life conditions. New guidelines have been released with regard to hepatitis C treatment from both European and American societies (Table 2) .
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